1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Mayinglong Pharmaceutical Group Co., Ltd.

Mayinglong Pharmaceutical Group Co., Ltd.

600993.SS
Mayinglong Pharmaceutical Group Co., Ltd.CN flagShanghai Stock Exchange
22.71
CNY
-0.44
- -
9.79BMarket Cap
Mayinglong Pharmaceutical Group Co., Ltd.
600993.SS
(Shanghai Stock Exchange)

Recent

price

22.71

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.74
3.32
3.55
3.7
3.78
4.15
4.87
4.05
5.11
6.31
6.46
7.87
8.19
7.29
8.68
8.98
8.66
Revenue per Share
0.28
0.32
0.4
0.43
0.47
0.52
0.58
0.74
0.41
0.84
0.97
1.08
1.11
1.03
1.23
1.35
1.29
Basic EPS, GAAP
-0.1
0.07
0.31
0.11
0.01
0.14
0.4
0.73
0.66
1.04
0.55
1.24
0.62
0.83
0.68
1.12
-0.39
Free Cash Flow per Basic Share
0.11
0.05
0.1
0.13
0.15
0.04
0.21
0.2
0.24
0.16
0.27
0.29
0.38
0.38
0.41
0.63
0.4
Dividend per Share
1.43
1.95
2.18
2.45
2.82
3.24
3.55
4.08
4.27
4.96
5.63
6.44
7.18
7.87
8.72
9.42
8.82
Book Value per Share
2.52
2.98
3.21
3.53
3.85
4.28
4.55
5.13
5.34
6.02
6.62
7.49
8.14
8.56
9.26
9.9
9.31
Tangible Book Value per Share
431
426
434
433
429
429
431
433
430
429
432
430
431
430
429
431
433
Basic Weighted Avg Shares
1,178
1,416
1,542
1,602
1,621
1,784
2,103
1,751
2,198
2,705
2,792
3,385
3,532
3,137
3,728
3,867
3,749
Sales/Revenue/Turnover
10.4
12.43
10.35
11.71
11.61
11.7
11.09
15.81
14.48
14.44
13.76
14.01
14.91
13.27
16.6
17.32
17.07
Operating Margin (%)
22
23
24
25
24
24
36
36
36
36
35
69
79
81
81
94
- -
Depreciation Expense
123
138
174
186
201
223
250
320
176
360
419
465
479
443
528
581
559
Net Income, GAAP
16.97
15.51
16
17.39
13.52
14.86
16.69
15.35
14.17
16.34
13.47
13.52
14.27
13.89
16.62
14.57
15.64
Effective Tax Rate (%)
10.4
9.73
11.27
11.63
12.43
12.52
11.9
18.28
8.02
13.31
15.01
13.72
13.55
14.13
14.17
15.04
14.92
Profit Margin (%)
721
918
1,061
1,128
1,167
1,244
1,382
1,726
1,804
2,100
2,281
2,696
3,368
3,091
3,171
3,040
2,841
Working Capital
- -
- -
- -
- -
- -
- -
5
4
2
5
76
73
522
194
76
70
69
LT Debt
1,127
1,320
1,433
1,566
1,699
1,887
2,017
2,271
2,347
2,631
2,947
3,314
3,616
3,870
4,201
4,515
4,270
Total Equity
8.81
11.58
9.23
9.71
9.31
9.27
9.34
10.34
11.21
12.32
10.81
11.74
11.24
8.34
11.87
12.42
12.12
Return on Invested Capital (%)
17.35
15.79
17.05
16.72
16.3
16.26
16.56
18.71
10.07
17.7
16.49
15.83
14.04
11.75
13
13.41
13.44
Return on Capital (%)
20.99
19.08
19.55
18.54
17.76
17.17
17.12
19.43
9.79
18.17
18.37
17.86
16.32
13.67
14.81
14.91
15.23
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
158
134
133
LT Borrowings
- -
- -
- -
LT Finance Leases
76
77
69
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
431
431
431
Market Capitalization
11,220
10,577
12,249

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
3,975
3,971
4,048
Cash, Cash Equivalents & STI
3,157
2,916
2,967
Accounts Receivable, Net
260
257
277
Inventories
278
271
281
Total Current Liabilities
804
863
1,207
Payables & Accruals
- -
- -
- -
ST Debt
158
134
133
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.16%
8.93%
7.46%
Free Cash Flow
43.06%
30.75%
63.76%
Net Income, GAAP
15.15%
7.15%
10.11%
Sales/Revenue/Turnover
8.99%
7.4%
3.72%
Total Cash Common Dividend
56.94%
19.98%
52.1%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
955
973
864
936
3,728
2025
969
980
1,029
- -
3,867
2026
1,012
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.46
- -
- -
- -
1.23
2025
0.47
- -
- -
- -
1.35
2026
0.49
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.41
2025
- -
- -
- -
- -
0.63
2026
- -
- -
- -
- -
- -
Similar Companies
Choom Holdings Inc. (CHOOF)
Walvax Biotechnology Co., Ltd. (300142.SZ)
Laurus Labs Limited (LAURUSLABS.BO)
Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS)
ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
Gabather AB (publ) (GABA.ST)
Business
Mayinglong Pharmaceutical Group Co., Ltd. specializes in the development, production, and sale of pharmaceuticals and health products, primarily focusing on anorectal health solutions. The company offers a broad range of products including proprietary medicines such as Ma Yinglong Musk Hemorrhoids Ointment and Suppository, Longzhu ointment, functional cosmetics (eye care, facial and body cleaning products), functional care items (infant paper, skin care, feminine products), functional foods that enhance digestion and kidney health, as well as medical devices and dietary supplements. Additionally, Mayinglong operates in hospital medical services and management, retail and wholesale of medical devices and pharmaceuticals, and provides hospital operations mainly across China. Founded in 1582 and headquartered in Wuhan, China, Mayinglong maintains significant market share in the domestic hemorrhoid treatment segment, with over 40% share and widespread brand recognition. In the recent 1-2 years, Mayinglong has pursued strategic growth through acquisitions and expansions including a notable acquisition of a 60% stake in Jiangxi Shuanghe Pharmaceutical Co., Ltd., enhancing its production capacity. The group also entered into a partnership involving the sale of an 86.816% stake in Shenzhen Daphne Pharmaceutical Co., Ltd. to Hangzhou Yunbai Pharmaceutical Technology Co., Ltd., reflecting active portfolio management. Mayinglong continues to invest heavily in research and development, allocating around 8-10% of annual revenue to innovate and expand its product portfolio, which includes over 60 formulations sold domestically and internationally. In 2023, the company launched over 30 new products and expanded its international footprint to more than 50 countries with certifications including GMP and ISO standards. Its revenue streams are diversified across traditional Chinese and Western medicines, over-the-counter products, prescription drugs, and healthcare services, supporting a balanced business model that integrates traditional medicine with modern pharmaceutical practices. The company emphasizes digital sales channels and brand awareness campaigns, having boosted its marketing budget significantly to reach broader markets domestically and abroad, particularly targeting Southeast Asia and Europe. Its comprehensive three-dimensional industrial structure comprises pharmaceuticals, medical services, pharmaceutical commerce, and hospital management. Mayinglong’s persistent innovation in formulations, market expansion, and strategic alliances underpin its leadership role in China’s pharmaceutical and healthcare industry.